Landmark EU Trial Pushes Personalized Breast Cancer Treatment into a New Era

BARCELONA, Spain – May 07, 2026 – A major European clinical trial aimed at revolutionizing the treatment of HER2-positive breast cancer has reached a critical juncture, signaling a potential shift from standardized protocols to highly personalized patient care. The DEFINITIVE project, a landmark Phase III trial funded by the European Union, announced at the ESMO Breast Cancer 2026 congress that it has surpassed 50% of its patient recruitment goal and has all clinical sites across seven countries fully operational.

This progress marks a pivotal moment for the trial and for the HER2DX diagnostic assay it evaluates. Developed by REVEAL GENOMICS, the test promises to provide a far more nuanced understanding of a patient's tumor than ever before, potentially allowing doctors to tailor therapies to improve quality of life without compromising survival—a long-sought goal in oncology.

Beyond a One-Size-Fits-All Approach

For decades, a diagnosis of HER2-positive breast cancer has been a double-edged sword. While the discovery of targeted therapies like trastuzumab transformed outcomes for this aggressive subtype, the standard of care often involves an intense regimen of chemotherapy and anti-HER2 drugs. This aggressive approach, while effective for many, can lead to significant, sometimes debilitating, side effects and raises the persistent issue of overtreatment for patients whose tumors may not require such a powerful response.

Conversely, some patients do not respond as well as hoped, indicating undertreatment and the need for a different strategy. The core challenge has been the inability to accurately predict which patients will benefit most from which combination of therapies. Traditional diagnostic methods, such as Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH), are crucial for identifying the presence of the HER2 protein but offer limited insight into the tumor's underlying biology and its likely response to treatment.

This is the gap the HER2DX genomic assay aims to fill. By moving beyond a simple positive or negative result, it seeks to provide a detailed biological road map for each individual patient’s cancer.

Decoding the Tumor with Genomic Intelligence

At the heart of the DEFINITIVE trial is the HER2DX test, the first diagnostic tool of its kind specifically formulated for HER2-positive breast cancer. It is not merely a confirmation of HER2 status but a sophisticated 27-gene expression profile that integrates a patient's clinical data—such as tumor size and lymph node involvement—with deep genomic information.

Using an artificial intelligence algorithm, the assay analyzes the tumor's immune response, cell proliferation rate, and the specific expression of the ERBB2 gene, which is responsible for the HER2 protein. From this complex data, it generates three distinct, clinically actionable scores:

• A risk of relapse score, which classifies a patient's long-term risk of the cancer returning as either high or low.
• A pathological complete response (pCR) likelihood score, which predicts the probability that a tumor will be completely eradicated by treatment administered before surgery (neoadjuvant therapy).
• An ERBB2 expression score, which provides a quantitative measure of the gene's activity.

This multi-faceted information empowers clinicians to make more informed decisions. For instance, a patient with a high pCR likelihood score might be a candidate for a less intensive, or "de-escalated," chemotherapy regimen, sparing them unnecessary toxicity. Conversely, a high-risk relapse score could prompt a more aggressive or extended treatment plan to improve their long-term prognosis.

Putting Precision to the Ultimate Test

The DEFINITIVE trial is designed to rigorously validate this approach. The prospective, randomized, phase III study has enrolled over half of its target of 304 patients with early-stage (II to IIIA) HER2-positive breast cancer. These participants are randomly assigned to one of two arms: a control group where treatment decisions are made according to standard local guidelines, and an experimental group where oncologists use the HER2DX assay to guide their therapeutic strategy.

This head-to-head comparison across 44 centers in Spain, Austria, France, Germany, Italy, Ireland, and Israel is crucial for proving the test's real-world value. The announcement that 33 of these sites are now actively recruiting, with recruitment in Israel already complete, demonstrates significant momentum and the broad support of the European oncology community.

"Having all 33 centres recruiting across 7 countries and reaching more than 50% enrolment is a remarkable achievement," said Dr. Tomás Pascual, a Principal Investigator at the Clínic Barcelona Comprehensive Cancer Centre, in a statement. "It reflects the commitment of our teams and patients, and the oncology community's belief in HER2DX as a tool to truly personalise BC treatment. ESMO 2026 is the perfect moment to share this momentum."

The trial's robust design, coordinated by leading European research groups like SOLTI in Spain and Unicancer in France, is intended to generate the high-level evidence needed to change clinical practice guidelines across the continent.

Redefining Success: Quality of Life and Economic Value

Perhaps the most forward-thinking aspect of the DEFINITIVE trial is its focus on endpoints that extend beyond traditional metrics of survival. A primary goal is to demonstrate that HER2DX-guided care can improve patients’ quality of life without any detriment to clinical outcomes. This acknowledges a growing movement in cancer care that views patient well-being and the reduction of treatment burden as essential components of success.

Furthermore, the trial incorporates a comprehensive cost-effectiveness analysis. If de-escalation of therapy proves safe and effective for a significant portion of patients, the financial implications for overburdened healthcare systems could be substantial. Reducing the use of expensive chemotherapy and anti-HER2 drugs, along with minimizing costs associated with managing severe side effects, presents a powerful economic argument for the adoption of genomic guidance.

This dual focus on patient experience and health economics is critical for navigating the complex path to widespread clinical use. The findings will be instrumental in discussions with national health technology assessment (HTA) bodies and insurers who determine whether new technologies are reimbursed and made available to patients. The trial is generating the exact kind of data these organizations require, proactively addressing the hurdles that have slowed the adoption of other medical innovations. The journey from a validated test to a reimbursed and integrated clinical tool is long, but the DEFINITIVE trial is a critical step in a journey towards a new standard of care in HER2-positive breast cancer.